Rocket Pharmaceuticals, Inc. Earnings Per Share (Basic)
Rocket Pharmaceuticals, Inc. (RCKT) reported Earnings Per Share (Basic) of $1.09 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-10
- Rocket Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-06-30 was $1.09.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.42.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.38.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.45.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for fiscal 2025 was -$2.01.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for fiscal 2024 was -$2.73.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for fiscal 2023 was -$2.92.
- Rocket Pharmaceuticals, Inc. earnings per share, basic for fiscal 2022 was -$3.26.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.09 10-Q · filed 2026-08-10 | $0.67 10-Q · filed 2026-08-10 | $0.29 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$0.15 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2026-03-31 | -$0.42 10-Q · filed 2026-05-07 | -$0.81 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.26 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.88 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-12-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$0.83 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.45 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.01 10-K · filed 2026-02-26 |
| 2025-09-30 | -$0.45 10-Q · filed 2025-11-06 | -$1.07 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$1.63 10-Q · filed 2025-11-06 | -$2.24 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-06-30 | -$0.62 10-Q · filed 2026-08-10 | -$1.18 10-Q · filed 2026-08-10 | -$1.79 derived: net income ÷ weighted average shares · filed 2026-08-10 | -$2.49 derived: net income ÷ weighted average shares · filed 2026-08-10 |
| 2025-03-31 | -$0.56 10-Q · filed 2026-05-07 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.87 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$2.61 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$1.33 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.07 derived: net income ÷ weighted average shares · filed 2026-02-26 | -$2.73 10-K · filed 2026-02-26 |
| 2024-09-30 | -$0.71 10-Q · filed 2025-11-06 | -$1.45 derived: net income ÷ weighted average shares · filed 2025-11-06 | -$2.11 10-Q · filed 2025-11-06 | -$2.75 derived: net income ÷ weighted average shares · filed 2025-11-06 |
| 2024-06-30 | -$0.74 10-Q · filed 2025-08-07 | -$1.40 10-Q · filed 2025-08-07 | -$2.04 derived: net income ÷ weighted average shares · filed 2025-08-07 | -$2.79 derived: net income ÷ weighted average shares · filed 2025-08-07 |
| 2024-03-31 | -$0.66 10-Q · filed 2025-05-08 | -$1.30 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$2.04 derived: net income ÷ weighted average shares · filed 2025-05-08 | -$2.85 derived: net income ÷ weighted average shares · filed 2025-05-08 |
| 2023-12-31 | -$0.64 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.38 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.19 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.92 10-K · filed 2025-02-27 |
| 2023-09-30 | -$0.75 10-Q · filed 2024-11-07 | -$1.56 derived: net income ÷ weighted average shares · filed 2024-11-07 | -$2.30 10-Q · filed 2024-11-07 | -$3.17 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-06-30 | -$0.82 10-Q · filed 2024-08-06 | -$1.55 10-Q · filed 2024-08-06 | -$2.42 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$3.29 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2023-03-31 | -$0.73 10-Q · filed 2024-05-07 | -$1.61 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.47 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$3.30 derived: net income ÷ weighted average shares · filed 2025-02-27 |
| 2022-12-31 | -$0.87 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$1.75 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$2.58 derived: net income ÷ weighted average shares · filed 2025-02-27 | -$3.26 10-K · filed 2025-02-27 |
| 2022-09-30 | -$0.87 10-Q · filed 2023-11-07 | -$1.70 derived: net income ÷ weighted average shares · filed 2023-11-07 | -$2.37 10-Q · filed 2023-11-07 | -$3.06 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-06-30 | -$0.83 10-Q · filed 2023-08-09 | -$1.50 10-Q · filed 2023-08-09 | -$2.19 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.97 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2022-03-31 | -$0.67 10-Q · filed 2023-05-05 | -$1.35 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.14 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.69 derived: net income ÷ weighted average shares · filed 2024-02-27 |
| 2021-12-31 | -$0.69 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$1.47 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.02 derived: net income ÷ weighted average shares · filed 2024-02-27 | -$2.67 10-K · filed 2024-02-27 |
| 2021-09-30 | -$0.79 10-Q · filed 2022-11-04 | -$1.33 derived: net income ÷ weighted average shares · filed 2022-11-04 | -$1.99 10-Q · filed 2022-11-04 | -$3.04 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-06-30 | -$0.55 10-Q · filed 2022-08-09 | -$1.20 10-Q · filed 2022-08-09 | -$2.25 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.79 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2021-03-31 | -$0.65 10-Q · filed 2022-05-06 | -$1.72 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.26 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.72 derived: net income ÷ weighted average shares · filed 2023-02-28 |
| 2020-12-31 | -$1.08 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$1.61 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.07 derived: net income ÷ weighted average shares · filed 2023-02-28 | -$2.52 10-K · filed 2023-02-28 |
| 2020-09-30 | -$0.53 10-Q · filed 2021-11-05 | -$0.98 derived: net income ÷ weighted average shares · filed 2021-11-05 | -$1.43 10-Q · filed 2021-11-05 | |
| 2020-06-30 | -$0.45 10-Q · filed 2021-08-09 | -$0.90 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$0.45 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$1.58 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |